Cellectar Biosciences, Inc. · NASDAQ:CLRB

Cellectar Biosciences — Investor Presentation (September 2016)

25 slides from Cellectar Biosciences's investor presentation, September 2016

  1. Slide 1: Cellectar Biosciences

    'G; @se CELLECTAR BIOSCIENCES NASDAQ: CLRB

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This slide presentation contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties t

  3. Slide 3: Investment Overview

    Investment Overview • Oncology-focused biopharmaceutical company in Madison, WI • Phospholipid Drug Conjugate (PDC) Delivery Platform – Phospholipid Ether cancer-targeting vehicle – Enables delivery of diverse oncologic payloads – Increases payload therapeutic window • Pipeline of PDC cancer therape

  4. Slide 4: Phospholipid Ether Cancer-Targeting Vehicle

    Phospholipid Ether Cancer-Targeting Vehicle • Proprietary small-molecule • Highly selective cancer and cancer stem cell (CSC) targeting • Uptake and prolonged retention in malignant cells – Proof of concept (POC) in broad range of cancers • Ability to attach diverse oncologic payloads • Extensive re

  5. Slide 5: PDC Cancer-Targeting Validation in Broad Range of Cancers

    PDC Cancer-Targeting Validation in Broad Range of Cancers In Vitro Mechanistic POC Malignant vs normal Prostate Glioma stem cells Multiple Myeloma • Lipid Raft Uptake • Cytoplasm & Cell Organelle Delivery • Prolonged Retention In Vivo POC • 70+ Cancer & CSC Models • Therapeutics & Imaging Colorectal

  6. Slide 6: PDC Diverse Payload Delivery Validation

    PDC Diverse Payload Delivery Validation Radioisotopes for Cancer Therapy • CLR 131: Multiple Myeloma • Iodine-125 Radioisotopes for Cancer Imaging • CLR 124: Glioma • Iodine-123 Fluorophores for Imaging-Guided Surgery • CLR 1502: Optical Imaging • CLR 1501 Chemotherapeutics for Cancer Therapy • CLR

  7. Slide 7: PDC Delivery Platform Overview

    PDC Delivery Platform Overview Phospholipid Drug Conjugate (PDC) Phospholipid Ether + Linker + Drug = PDC (PLE) Linker Drug Cancer-Targeting Vehicle Versatile Chemistry Untargeted Payload Cancer-targeted Payload Enabling Targeted Delivery of Diverse Oncologic Payloads 7

  8. Slide 8: PDC vs. ADC Targeting & Payload Delivery

    PDC vs. ADC Targeting & Payload Delivery Phospholipid Ether-Drug Conjugates Antibody-Drug Conjugates Target: Lipid rafts/ Caveolae Target: Tumor-specific antigens Delivery: Cell cytoplasm Delivery: Cell surface Immunogenic: No Immunogenic: Potentially 8

  9. Slide 9: PDC Delivery Platform Summary

    PDC Delivery Platform Summary DELIVERY PLATFORM PDC ADC Description PLE: Small-Molecule Antibody: Biologic Manufacturing Low High Cost/Complexity Safety No Immunogenicity Potential Immunogenicity Cancer Targeting Cancer Selective Antigen Selective --Cancer Stem Cell Yes ? -- Brain Metastases Yes ? T

  10. Slide 10: PDC Product Development Pipeline

    PDC Product Development Pipeline PDC Program Payload Indication Discovery Pre-IND Phase I Phase II Collaboration Hematologic Malignancies Phase II- Expected 1H 2017 CLR 1311 Iodine-131 Multiple Myeloma Phase I Micrometast. CLR 125 Iodine-125 Disease Phase I Ready CLR 1800-P Proprietary TBD2 Pre-IND

  11. Slide 11: CLR 131: Lead PDC Radiotherapeutic Product

    CLR 131: Lead PDC Radiotherapeutic Product • Payload: Iodine-131 – Cytotoxic radioisotope – Thyroid cancer Tx • PDC: CLR 131 Linker 131I – Targeted cytotoxic delivery – Clinical efficacy and safety demonstrated in humans (N=25) – Solid tumor MTD (≤ 31.25mCi/m2) – Hematologic cancer MTD under evaluat

  12. Slide 12: CLR 131: Clinical Rationale For Multiple Myeloma

    CLR 131: Clinical Rationale For Multiple Myeloma • Multiple Myeloma – Incurable hematologic cancer – Orphan Designation – Unmet need in relapsed/refractory setting – Established radiosensitivity – Quantitative response criteria • M-protein marker • Free Light Chain (FLC) • CLR 131 – In vivo MM cell

  13. Slide 13: CLR 131: Phase 1 R/R Multiple Myeloma Study Overview

    CLR 131: Phase 1 R/R Multiple Myeloma Study Overview • Multi-center, open label, dose escalation trial initiated Q2 2015 • Primary objective: – Characterize safety & tolerability • Secondary objectives: – Establish phase 2 dose – Assess therapeutic activity • Dose escalation < 2 of 6 DLT’s – 85 day

  14. Slide 14: CLR 131: Cohort 1 Patient Outcomes

    CLR 131: Cohort 1 (12.5 mCi/m2) Patient Outcomes IMWG1 Progression Patient Adverse Events Prior Treatments Age Response Free Number ≥ Grade 2 Assessment Survival Decreased Neutrophils 2 12 Systemic 101 55 Anemia 3 Stable Disease 2 months Regimens Decreased WBC 3 Progressive 1022 3 Systemic Regimens

  15. Slide 15: CLR 131: Cohort 1 Partial Responders

    CLR 131: Cohort 1 (12.5mCi/m2) Partial Responders Free Light Chain Assay Measurement 0.0% 131 Dose -10.0% -20.0% % Change from Baseline -30.0% -40.0% -50.0% Partial Repsonse1 -60.0% -70.0% 1 22 43 64 85 # of Days 15 Patient #3 Patient #5 1. IMWG Criteria, If Serum or Urine M-Proteins Are Not Measure

  16. Slide 16: CLR 131: Multiple Myeloma Market Overview

    CLR 131: Multiple Myeloma Market Overview • Unmet need remains in the relapsed or refractory setting • 2nd most common hematologic cancer • Prevalence ~ 90,000 • Incidence ~ 26,850 • Relapsed/Refractory ~ 13,000 • Global MM drug market (7MM) • $5.85B (2013) - $8.82B (2022) – CAGR ~3.93%1 • Premium p

  17. Slide 17: CLR 131: Significant Return in Relapsed Refractory HemOnc

    CLR 131: Significant Return in Relapsed Refractory HemOnc Multiple Myeloma Expected FDA Approval 2020 ~$400 Million/yr. Top Line Revenue Potential1 Relapsed/Refractory CLR 131 Sales Scenario • Multiple Myeloma $450,000,000 • Acute Myeloid Leukemia $400,000,000 Acute Lymphocytic Leukemia • Acute Lymp

  18. Slide 18: CLR 131: Phase 2 Clinical Study

    CLR 131: Phase 2 Clinical Study Cellectar Biosciences Announces $2 Million NCI SBIR Contract for a Phase 2 Clinical Study Company to Accelerate CLR 131 Research in Multiple Myeloma and Other Hematologic Malignancies MADISON, Wis., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq

  19. Slide 19: PDC Chemotherapeutic Program Overview

    PDC Chemotherapeutic Program Overview • Objective – Develop chemotherapeutic PDCs with improved efficacy & tolerability • Clinical rationale – Chemotherapeutics highly effective, yet highly toxic drugs – Combining the unique targeting capabilities of PDCs with cytotoxic drugs improves therapeutic in

  20. Slide 20: PDC Chemotherapeutic Program Progress

    PDC Chemotherapeutic Program Progress • Five different PDCs currently being evaluated – Paclitaxel, vorinostat, gemcitabine, GEL, MER – Paclitaxel (CLR 1602) selected for in vivo assessment • Ongoing in vitro studies – Plasma stability – Formulation development – Cytotoxic activity • CLR 1602 – Issu

  21. Slide 21: Pierre Fabre PDC Collaboration

    Pierre Fabre PDC Collaboration • Announced December 2015 – Launched Q1 2016 • Pierre Fabre provides selection of proprietary cytotoxins • Objectives – Co-design library of PDCs • Lead product conjugation completed – Conduct in vitro assessments – Conduct in vivo POC studies • Targeting/biodistributi

  22. Slide 22: Financial Summary

    Financial Summary Capitalization as of June 30, 2016 Common Stock Outstanding 5,368,235 Warrants (strike price primarily @ $3.04) 4,629,842 Stock Options 397,882 Fully Diluted Securities Outstanding 10,395,959 Cash Position $7,922,144 22

  23. Slide 23: Company Milestones

    Company Milestones Q3 - Q4 2015 Q1 - Q2 2016 Q3 2016 - 1H 2017 PDC Delivery Platform Introduced Pierre Fabre - Q1 NCI Fast Track Award - Q3 -Therapeutic Focus -CLR 131 Phase 2 Award - $2M -CTX Program -PDC Collaboration Initiated -Phase 2 Clinical Study in Hematologic Cancers -Collaboration Model $3

  24. Slide 24: Company Leadership

    Company Leadership Management Board of Directors HIP Innovation Technology- EVP & HIP Innovation Technology- EVP & Jim Caruso Jim Caruso COO; Allos Therapeutics- EVP & CCO; COO; Allos Therapeutics- EVP & CCO; President, CEO and Director President, CEO and Director BCI, Novartis, BASF, BMS BCI, Novar

  25. Slide 25: Investment Overview

    Investment Overview • Oncology-focused biopharmaceutical company in Madison, WI • Phospholipid Drug Conjugate (PDC) Delivery Platform – Phospholipid Ether cancer-targeting vehicle – Enables delivery of diverse oncologic payloads – Increases payload therapeutic window • Pipeline of PDC cancer therape

Cellectar Biosciences — Investor Presentation (September 2016) on 6ix